Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CHEMICAL COMPOUNDS
Document Type and Number:
WIPO Patent Application WO/2006/062476
Kind Code:
A1
Abstract:
The present invention concerns a compound of formula (I): wherein R1 is C1-4 alkyl, or benzyl optionally substituted by halogen, C1-4 alkyl (optionally substituted by halogen or C1-4 alkoxy), C1-4 alkoxy, C1-4 alkoxycarbonyl, nitro or cyano; and a process for preparing a compound of formula (I).

Inventors:
NOBLE ALLISON (GB)
PERRY MATTHEW (GB)
Application Number:
PCT/SE2005/001864
Publication Date:
June 15, 2006
Filing Date:
December 07, 2005
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ASTRAZENECA AB (SE)
NOBLE ALLISON (GB)
PERRY MATTHEW (GB)
International Classes:
C07C25/13; C07C17/26; C07C17/269; C07C25/18; C07C67/343; C07C69/76; C07C
Domestic Patent References:
WO2005097775A12005-10-20
WO2003068743A12003-08-21
Foreign References:
US20040235894A12004-11-25
US5489592A1996-02-06
US3985799A1976-10-12
Other References:
DATABASE CAPLUS [online] "Fluorobenzonitrile derivatives", XP002997982, accession no. STN Database accession no. (1981:568830)
KRESS T.H. ET AL.: "Synthesis, Stability, and Reactions of 2,6-Dichlorophenyllithium", SYNTHESIS, vol. 10, 1988, pages 803 - 805, XP000990471
MALYKHIN E.V. ET AL.: "Preparation of 2,6-difluoro-n-alkylbenzenes from 1,3-difluorobenzene Transformation of 2,6-difluorotoluene to the corresponding benzaldehyde via benzyl chloride", JOURNAL OF FLUORINE CHEMISTRY, vol. 91, 1998, pages 19 - 20, XP004131562
LEROUX F. ET AL.: "N-(4-Biphenylmethyl)imidazoles as Potential Therapeutics for the Treatment of Prostate Cancer: Metabolic Robustness Due to Fluorine Substitution", HELVETICA CHIMICA ACTA, vol. 86, 2003, pages 2671 - 2686, XP002996593
Attorney, Agent or Firm:
Astrazeneca (Södertälje, SE)
Download PDF:
Claims:
CLAIMSwherein R1 is C
1. 4 alkyl, or benzyl optionally substituted by halogen, C1. 4 alkyl (optionally substituted by halogen or C1. 4 alkoxy), C1. 4 alkoxy, C1. 4 alkoxycarbonyl, nitro or cyano.
2. A compound of formula (I) as claimed in claim 1 wherein R1 is Cj. 4 alkyl.
3. A compound of formula (I) as claimed in claim 1 or 2 wherein R1 is methyl.
4. A process for the preparation of a compound of formula (I), the process comprising: a. reacting a compound of formula (II): with a suitable strong base at a temperature in the range . 80 to . 30 0C in a suitable solvent to form a carbanion of compound of formula (II); and, b. reacting the carbanion of compound of formula (II) with a compound R1L, wherein L is a suitable leaving group, in a suitable solvent, and at a temperature in the range . 80 to . 30 0C.
5. A process as claimed in claim 4 wherein the strong base is a C1. 1O alkyl lithium or a di. C^o alkyl lithium amide base.
6. A process as claimed in claim 4 or 5 wherein the strong base is π. butyl lithium.
7. A process as claimed in claim 4, 5 or 6 wherein L is halogen, triflate or methylsulfate.
8. A process as claimed in claim 4, 5, 6 or 7 wherein steps a and b are carried out at a temperature in the range . 60 to . 30 0C.
9. A process as claimed in claim 4, 5, 6, 7 or 8 wherein, in step b, the carbanion of a compound of formula (II) is added to the compound R1L.
10. A process as claimed in claim 4, 5, 6, 7, 8 or 9 wherein the suitable solvent for steps a and b is an ether.
Description:
CHEMICAL COMPOUNDS

The present invention concerns 3-alkyl-l,2-dichloro-4-fluorobenzene compounds and a process for their preparation. 3-Alkyl-l,2-dichloro-4-fluorobenzene compounds are useful in the preparation of modulators (for example antagonists) of CCR3 chemokine receptor activity. For example 3-alkyl-l,2-dichloro-4-fluorobenzene compounds are useful pharmaceutical intermediates in the preparation of [(phenoxy)-[l,4']bipiperidinyl-r-yl]-(phenyl)-methanone derivatives (see, for example, WO03/004487, WO2004/099144 and WO2004/087659). Thus, the present invention provides a compound of formula (I):

wherein R 1 is C 1-4 alkyl, or benzyl optionally substituted by halogen, C 1-4 alkyl (optionally substituted by halogen or C 1-4 alkoxy), C 1-4 alkoxy, C 1-4 alkoxycarbonyl, nitro or cyano.

Halogen is, for example, fluoro or chloro. Alkyl is straight or branched chain and is, for example, methyl, ethyl, wo-propyl, n- butyl, sec-butyl or tert-butyl.

Alkoxy is straight or branched chain and is, for example, methoxy or ethoxy.

In one aspect the invention provides a compound of formula (I) wherein R 1 is C 1-4 alkyl or benzyl. In another aspect the present invention provides a compound of formula (I) wherein R 1 is C 1-4 alkyl (for example ethyl or methyl). In yet another aspect the present invention provides a compound of formula (I) wherein R 1 is methyl.

In a further aspect the present invention provides a process for preparing a compound of formula (I), the process comprising: a. reacting a compound of formula (II):

with a suitable strong base at a temperature in the range -80 to -30 0 C in a suitable solvent to form a carbanion of a compound of formula (II); and, b. reacting the carbanion of a compound of formula (II) with a compound R 1 L,

wherein L is a suitable leaving group, in a suitable solvent, and at a temperature in the range -80 to -10 0 C (for example -50 to -30 0 C).

Suitable strong bases are, for example, C 1-10 alkyl (for example C 1-6 alkyl, such as C 4 ) lithiums (such as π-butyl lithium, sec-butyl lithium), a (Ii-C 1-1O alkyl (for example (Ii-C 1- g alkyl) lithium amide base (such as lithium dusopropylamide), an aryl lithium (such as a phenyl lithium) or an arylalkyl lithium (such as a benzyl lithium).

In a still further aspect of the invention a suitable strong base is, for example a C 1-6 alkyl (for example C 4 ) lithium (such as n-butyl lithium, sec-butyl lithium) or a di-C 1-6 alkyl lithium amide base (such as lithium diwø-propylamide). In another aspect of the invention the strong base is n-butyl lithium.

A suitable solvent for steps a and b of the process is an ether (for example tetrahydrofuran [THF], methyl tert-butyl ether or dioxan).

The leaving group L is, for example, halogen (such as bromine or iodine), triflate or methylsulfate. In a further aspect of the invention L is methylsulfate. In another aspect the present invention provides a process as hereinbefore described wherein, in step b, the carbanion of a compound of formula (II) is added to the compound R 1 L.

In yet another aspect the present invention provides a process as hereinbefore described whereinbetween 1 and 1.5 molar equivalents of strong base is used {such as between 1.1 and 1.25 equivalents (for example between 1.15 and 1.2 equivalents) of strong base}.

In a further aspect the present invention provides a process as hereinbefore described wherein an excess of compound R 1 L over strong base is used.

In yet another aspect the present invention provides a process as hereinbefore described wherein, in step b, the compound R 1 L is added to the carbanion of a compound of formula (II).

In a further aspect the present invention provides a process as hereinbefore described wherein steps a and b are carried out at a temperature in the range -60 to -10 0 C (for example -60 to -30 0 C). The invention will now be illustrated by the following non-limiting Examples. In the Examples the following apply, unless stated otherwise:

(i) when given, 1 H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane

(TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 (CD 3 SOCD 3 ) or CDCl 3 as the solvent unless otherwise stated;

(ii) Reverse phase analytical HPLC was run on a Hewlett Packard Series 1100 using Waters "Symmetry" C8 column 3.5μm; 4.6 x 50mm column. The gradient was either:

"Standard" (0.1% Ammonium acetate/ Acetonitrile 75% to 5% in 3 minutes- 2 mL/minutes), or,

"Fast" (0.1% Ammonium acetate/Acetonitrile 45% to 5% in 2.5 minutes; 2 mL/minutes); and,

(iii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H) + .

EXAMPLE 1

This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene. π-Butyl lithium (75ml, 2.48M in hexanes, Aldrich, 1.1 equivalents) is added over Ih by syringe pump to a solution of l,2-dichloro-4-fluorobenzene (20ml, 28.1g, lequivalents) in anhydrous THF (180ml) at -40 0 C, keeping the temperature between -45 °C and -40 °C. The solution is stirred at -40 0 C for 15-30 minutes and then a solution of dimethylsulfate (19ml, 1.2equivalents) in THF (20ml) is added over Ih by syringe pump, keeping temperature between -45 0 C and -40 °C. The mixture is then stirred at -40 °C for 15- 30minutes and then allowed to warm to room temperature. To the solution is then added 5% w/v (or 5% w/w) brine (60ml) followed by aqueous ammonia solution (0.88 NH 3 ,

40ml). The mixture is stirred vigorously for 30minutes and then the layers separated. The bottom layer is discarded and the top layer washed with 5% w/v brine solution (100ml) by again stirring for 30minutes and then separating the layers. The top layer is then analysed for product by GC, evaporated to dryness and if necessary purified by distillation. Gas Chromatography Analysis showed 87.1% l,2-dichloro-4-fluoro-3- methylbenzene, 2.1% of a dimethylated fluorodichlorobenzene and 8.0% of a second dimethylated fluorodichlorobenzene.

NMR δcDcis: 2.35 (d, 3H, J = 2.4Hz), 6.92 (t, IH, J = 8.8Hz), 7.27 (ddq, IH, J =

8.8, 5.4, 0.6Hz)ppm.

MS (GC-MS) M + (EI) = ITS.

EXAMPLE 2 This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene. l,2-dichloro-4-fluorobenzene (30 mL) and N,Λf,Λ^ΛMetramethylethane-l,2- diamine (45 mL) in THF (400 mL) were cooled to -78 0 C. sec-Butyl lithium (1.3M, 315 mL) was added dropwise over 2h. The resultant mixture was stirred at -78 0 C for 4h. Iodomethane (18.2 mL) was added. The reaction mixture was allowed to warm to room temperature overnight. Saturated NH 4 Cl solution was added and the mixture was extracted using ether and ethyl acetate, the organic layers were combined, washed with 2M HCl solution, dried over MgSO 4 and the solvents were removed. The residue was distilled under reduced pressure (water aspirator, ca 20 mmHg) to give the title compound (17.3g; b.pt. 75 0 C at water aspirator, approximately 20 mmHg). HPLC (standard gradient) retention time 2.63 minutes.

EXAMPLE 3

This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene l,2-Dichloro-4-fluorobenzene (0.25 mL) was dissolved in THF (2 mL) and the solution was cooled to -78 °C. n-Butyl lithium (2.5M in hexanes, 1.0 mL) was added dropwise and the resulting solution was stirred at -78 °C for 15 minutes then allowed to warm to -40 °C. The solution was held at -40 °C for 15 minutes then recooled to -78 °C and methyl triflate (0.30 mL) was added dropwise. The resulting solution was allowed to warm slowly to ambient temperature. Aqueous ammonium chloride was added and the reaction mixture was extracted twice with ether. The organic phases were combined and washed with brine, dried, filtered and concentrated. HPLC of the residue shows the major component to be the title compound (Retention time standard gradient 2.58, identical to a previously prepared sample of title compound).

EXAMPLE 4

This Example illustrates the preparation of l,2-dichloro-3-ethyl-4-fluorobenzene. l,2-Dichloro-4-fluorobenzene (1.3 ml) was dissolved in THF (10 ml) and the resultant solution was cooled to -78 °C. /z-Butyl lithium (1OM, 1.2 ml) was added

dropwise over 5 minutes. The resultant solution was stirred at -78 0 C for 5 minutes then allowed to warm to ca -40 0 C and held at this temperature for 15 minutes. The solution was cooled to -78 0 C and then iodoethane (1.24 ml) was added. The resultant solution was allowed to warm to 10 °C. pH7 Buffer was added followed by ethyl acetate and diethyl ether. The phases were separated and the aqueous phase was extracted twice with diethyl ether. The organics were combined, washed with brine, dried, filtered and concentrated to give the title compound, contaminated with diethyl ether and ethyl acetate (2.37 g). GCMS 97.75% retention time 4.61 minutes (M + (EI) 192/194/196; bp 177) (Agilent 6890/5973 GC/MSD HP5-MS column, 30m x 0.25mm with a film thickness of 0.25um, 90-310 °C at 30 °C/minutes).

1 H NMR δ ( c DCB ) 1.18 (3H, t), 2.84 (2H, qd), 6.92 (IH, t), 7.27 (IH, dd).

The following compounds were prepared analogously using appropriate alkylating agents:

EXAMPLE 5

2-Benzyl-3,4-dichloro-l-fluorobenzene using benzyl bromide HPLC (fast) retention time 1.94.

1 H NMR δ( C Dci 3 ) 4.19 (2H, d), 6.98 (IH, t), 7.16 - 7.36 (6H, m).

EXAMPLE 6

Methyl 3-(2,3-dichloro-6-fluorobenzyl)benzoate using 3-bromomethyl-benzoic acid methyl ester

HPLC (fast) retention time 1.77. 1 H NMR δ ( c DCL3 ) 3.90 (3H, s), 4.23 (2H, d), 6.97 - 7.04 (IH, m), 7.30 - 7.42 (3H, m), 7.88 (IH, d), 7.93 (IH, s).

EXAMPLE 7

This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene. n-Butyl lithium (33.9kg, 2.7M in hexanes, Aldrich, 1.17equivalents) was added over 35minutes to a solution of l,2-dichloro-4-fluorobenzene (17.95kg, lequivalents) in anhydrous THF (105L) at -45°C, keeping the temperature between -45 0 C and -4O 0 C. The solution was then cooled to -55°C and added to a solution of dimethylsulfate (16.4kg,

1.2equivalents) in THF (96kg) at -19 0 C over 30minutes, temperature -15°C. The mixture was then warmed to 20.5 0 C. To the solution was then added a mixture of sodium chloride (1.9kg) and ammonium hydroxide solution (22kg, 28%) as a solution in water (36L) at 21 0 C. The mixture was stirred vigorously for 30minutes at 20-25 0 C and then the layers separated. The bottom layer was discarded and the top layer washed with a solution of sodium chloride (3.3kg) in water (60L) by stirring for 30minutes at 20-25 0 C and then separating the layers. The lower layer was discarded and the solvent removed from the top layer by distillation at 40 0 C and 60mbar. The residue was then purified by distillation at 90-100 0 C and 11-lOmbar to give the l,2-dichloro-4-fluoro-3-methylbenzene (14.8kg, 76%) as a colourless, waxy solid. (GC: 0.1% starting fluorodichlorobenzene, 93.18% product, 0.2% ethylated fluorodichlorobenzene, 1.57% first dimethylated fluorodichlorobenzene, 4.48% second dimethylated fluorodichlorobenzene.)

The product was redistilled together with a second batch at 102-105 0 C and 15.5- 13mbar to give the title compound (29.01kg, 78%) as a colouless waxy solid. (GC 0.55% starting fluorodichlorobenzene, 96.99% title compound, 0.22% ethylated fluorodichlorobenzene, 0.6% first dimethylated fluorodichlorobenzene, 1.64% second dimethylated fluorodichlorobenzene.)

NMR δcDcis: 2.35 (d, 3H, J = 2.4Hz), 6.92 (t, IH, J = 8.8Hz), 7.27 (ddq, IH, J = 8.8, 5.4, 0.6Hz). MS (GC-MS) M + (EI) = 178

EXAMPLE 8

This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene Lithium di-wø-propylamide (11.3ml, 1.8M, 1.2equivalents) was added over lOminutes to a solution of l,2-dichloro-4-fluorobenzene (2ml, 2.8g, lequivalents) in anhydrous THF (20ml) at -60 0 C, keeping the temperature below -60 0 C. The solution was stirred at -60 0 C for 20minutes, warmed to -40 0 C, stirred at -40 0 C for 30minutes and then cooled to -60 0 C. A solution of dimethylsulfate (2.25ml, 1.4equivalents) in THF (2ml) was added dropwise over 20minutes, keeping temperature between -6O 0 C and -55°C. The mixture was stirred at -60 0 C for 30minutes, warmed to room temperature overnight and then quenched with saturated brine solution (10ml). Diethylether (10ml) was added, followed by aqueous ammonia solution (0.88 NH 3 , 20ml). The mixture was stirred for 30minutes at room temperature and the top layer analysed for product by GC. (GC: 81.6%

title compound, 2.1% first dimethylated fluorodichlorobenzene, 11.9% second dimethylated fluorodichlorobenzene.)